{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:58:48Z","timestamp":1790625528808,"version":"4.1.0"},"reference-count":186,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Liver cirrhosis is marked by sodium and water retention, portal hypertension and sharply reduced survival after decompensation. Sodium\u2013glucose cotransporter-2 inhibitors (SGLT2i) induce insulin-independent glycosuria and natriuresis and have proven cardio-renal benefits, prompting interest in their role as adjuncts for ascites. This review synthesizes current evidence on efficacy, safety and mechanistic plausibility of SGLT2i in cirrhosis. Observational cohorts and case series suggest that adding SGLT2i to standard diuretics increases natriuresis, lowers ascites burden and paracentesis requirements, improves weight and aminotransferases and may reduce hepatic decompensation and hepatocellular carcinoma risk. Safety remains paramount: hypotension, acute kidney injury and hepatorenal syndrome-related acute kidney injury, genitourinary infections, electrolyte disturbances and rare euglycemic ketoacidosis necessitate careful patient selection, slow titration and close monitoring, especially in decompensated disease and when combined with loop diuretics or mineralocorticoid receptor antagonists. Overall, the balance of data supports cautious optimism: SGLT2i represent a promising adjunct within protocolized care pathways for selected patients, while definitive trials powered for hepatic outcomes are still required to clarify indications, timing, dosing and long-term impact.<\/jats:p>","DOI":"10.3390\/life15121788","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T08:59:46Z","timestamp":1763715586000},"page":"1788","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["SGLT2 Inhibitors and Liver Cirrhosis: Hype or Hope?"],"prefix":"10.3390","volume":"15","author":[{"given":"Olga","family":"Brusnic","sequence":"first","affiliation":[{"name":"Department of Internal Medicine VII, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, Gheorghe Marinescu Street No. 38, 540136 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5710-9109","authenticated-orcid":false,"given":"Danusia Maria","family":"Onisor","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine VII, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, Gheorghe Marinescu Street No. 38, 540136 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6646-1585","authenticated-orcid":false,"given":"Adrian","family":"Boicean","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Lucian Blaga University of Sibiu, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7255-0835","authenticated-orcid":false,"given":"Corina","family":"Porr","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Lucian Blaga University of Sibiu, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6493-3673","authenticated-orcid":false,"given":"Florin Daniel","family":"Sofonea","sequence":"additional","affiliation":[{"name":"Faculty of Social Sciences, Lucian Blaga University of Sibiu, 550012 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Anderco","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Lucian Blaga University of Sibiu, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9111-6088","authenticated-orcid":false,"given":"Cristian","family":"Ichim","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Lucian Blaga University of Sibiu, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: A systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Vos","year":"2020","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Mokdad, A.A., Lopez, A.D., Shahraz, S., Lozano, R., Mokdad, A.H., Stanaway, J., Murray, C.J., and Naghavi, M. (2014). Liver cirrhosis mortality in 187 countries between 1980 and 2010: A systematic analysis. BMC Med., 12.","DOI":"10.1186\/s12916-014-0145-y"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12072-017-9808-z","article-title":"New concepts on the clinical course and stratification of compensated and decompensated cirrhosis","volume":"12","author":"Morabito","year":"2018","journal-title":"Hepatol. Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies","volume":"44","author":"Pagliaro","year":"2006","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/qjmed\/hcm121","article-title":"Fluid retention in cirrhosis: Pathophysiology and management","volume":"101","author":"Kashani","year":"2008","journal-title":"QJM"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1111\/bcp.16139","article-title":"A potential novel treatment for cirrhosis-related ascites: Empagliflozin is safe and tolerable in advanced chronic liver disease","volume":"90","author":"Shen","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/cld.714","article-title":"SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites","volume":"11","author":"Saffo","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"547","DOI":"10.5604\/01.3001.0012.0916","article-title":"New Insights About Albumin and Liver Disease","volume":"17","author":"Carvalho","year":"2018","journal-title":"Ann. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"ElBaset, M.A., Salem, R.S., Ayman, F., Ayman, N., Shaban, N., Afifi, S.M., Esatbeyoglu, T., Abdelaziz, M., and Elalfy, Z.S. (2022). Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK\/SIRT-1\/HIF-1\u03b1 Pathway in Halting Liver Fibrosis. Antioxidants, 11.","DOI":"10.3390\/antiox11112152"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.34067\/KID.0002772021","article-title":"SGLT2 Inhibitors: Physiology and Pharmacology","volume":"2","author":"Wright","year":"2021","journal-title":"Kidney360"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Nevola, R., Villani, A., Imbriani, S., Alfano, M., Criscuolo, L., Beccia, D., Ruocco, R., Femine, A.D., Gragnano, F., and Cozzolino, D. (2023). Sodium-Glucose Co-Transporters Family: Current Evidence, Clinical Applications and Perspectives. Front. Biosci.-Landmark, 28.","DOI":"10.31083\/j.fbl2805103"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","article-title":"Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology","volume":"26","author":"Ferrannini","year":"2017","journal-title":"Cell Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/MNH.0000000000000584","article-title":"Renal effects of SGLT2 inhibitors: An update","volume":"29","author":"Nespoux","year":"2020","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/MNH.0000000000000187","article-title":"Sodium glucose cotransporter 2 inhibition in the diabetic kidney: An update","volume":"25","author":"Novikov","year":"2016","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Tang, J., Ye, L., Yan, Q., Zhang, X., and Wang, L. (2022). Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.800490"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Fonseca-Correa, J.I., and Correa-Rotter, R. (2021). Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review. Front. Med., 8.","DOI":"10.3389\/fmed.2021.777861"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e016270","DOI":"10.1161\/JAHA.120.016270","article-title":"Molecular, Cellular, and Clinical Evidence That Sodium-Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart Failure","volume":"9","author":"Packer","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e2518470","DOI":"10.1001\/jamanetworkopen.2025.18470","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors and Serious Liver Events in Patients With Cirrhosis","volume":"8","author":"Vignarajah","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_19","first-page":"18","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_20","first-page":"364","article-title":"Empagliflozin (Jardiance): A Novel SGLT2 Inhibitor for the Treatment of Type-2 Diabetes","volume":"40","author":"Ndefo","year":"2015","journal-title":"P. T Peer-Rev. J. Formul. Manag."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lu, Q., Li, X., Liu, J., Sun, X., Rousselle, T., Ren, D., Tong, N., and Li, J. (2019). AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases. Biosci. Rep., 39.","DOI":"10.1042\/BSR20181995"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s12272-020-01237-y","article-title":"Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia\/reperfusion injury through HIF-1\u03b1\/VEGF signaling pathway","volume":"43","author":"Rifaai","year":"2020","journal-title":"Arch. Pharm. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e007197","DOI":"10.1161\/CIRCHEARTFAILURE.120.007197","article-title":"Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors: Potential Role in Mediating the Heart Failure Benefits of SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors","volume":"13","author":"Packer","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/liv.15851","article-title":"Sodium\u2013glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use","volume":"44","author":"Siafarikas","year":"2024","journal-title":"Liver Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s10620-024-08667-4","article-title":"Safety and Efficacy of Dapagliflozin in Recurrent Ascites: A Pilot Study","volume":"70","author":"Singh","year":"2025","journal-title":"Dig. Dis. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s43066-024-00383-y","article-title":"Empagliflozin as a novel therapy for cirrhotic refractory ascites: A randomized controlled study","volume":"14","author":"Bakosh","year":"2024","journal-title":"Egypt. Liver J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/jdi.13255","article-title":"Sodium\u2013glucose cotransporters: Functional properties and pharmaceutical potential","volume":"11","author":"Sano","year":"2020","journal-title":"J. Diabetes Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/MNH.0000000000000152","article-title":"Sodium-glucose cotransport","volume":"24","author":"Poulsen","year":"2015","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Watabe, E., Kawanabe, A., Kamitori, K., Ichihara, S., and Fujiwara, Y. (2024). Sugar binding of sodium\u2013glucose cotransporters analyzed by voltage-clamp fluorometry. J. Biol. Chem., 300.","DOI":"10.1016\/j.jbc.2024.107215"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Mateoc, T., Dumitrascu, A.-L., Flangea, C., Puscasiu, D., Vlad, T., Popescu, R., Marina, C., and Vlad, D.-C. (2025). SGLT2 Inhibitors: From Structure\u2013Effect Relationship to Pharmacological Response. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26146937"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"102055","DOI":"10.1016\/j.molmet.2024.102055","article-title":"PET imaging of sodium-glucose cotransporters (SGLTs): Unveiling metabolic dynamics in diabetes and oncology","volume":"90","author":"Klimek","year":"2024","journal-title":"Mol. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of Human Sodium Glucose Transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors","volume":"75","author":"Zelniker","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1074\/jbc.M117.779520","article-title":"SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy","volume":"292","author":"Wang","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"F1224","DOI":"10.1152\/ajprenal.00370.2019","article-title":"Nephrotic Syndrome Study Network (NEPTUNE) Renal SGLT mRNA expression in human health and disease: A study in two cohorts","volume":"317","author":"Ambinathan","year":"2019","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: Impact of SGLT2 inhibitors","volume":"17","author":"DeFronzo","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"82","DOI":"10.36628\/ijhf.2022.0030","article-title":"SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence","volume":"5","author":"Talha","year":"2023","journal-title":"Int. J. Heart Fail."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/jdi.12644","article-title":"Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus","volume":"8","author":"Kashiwagi","year":"2017","journal-title":"J. Diabetes Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"C525","DOI":"10.1152\/ajpcell.00143.2024","article-title":"Mechanisms of heart failure and chronic kidney disease protection by SGLT2 inhibitors in nondiabetic conditions","volume":"327","author":"Girardi","year":"2024","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Tsai, K.-F., Chen, Y.-L., Chiou, T.T.-Y., Chu, T.-H., Li, L.-C., Ng, H.-Y., Lee, W.-C., and Lee, C.-T. (2021). Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases. Antioxidants, 10.","DOI":"10.3390\/antiox10081166"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: Mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Gao, Y.-M., Feng, S.-T., Wen, Y., Tang, T.-T., Wang, B., and Liu, B.-C. (2022). Cardiorenal protection of SGLT2 inhibitors\u2014Perspectives from metabolic reprogramming. eBioMedicine, 83.","DOI":"10.1016\/j.ebiom.2022.104215"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/j.ackd.2014.03.003","article-title":"Cardiovascular Complications of Diabetic Kidney Disease","volume":"21","author":"Patel","year":"2014","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.biopha.2018.07.157","article-title":"Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: An update on glucose toxicity","volume":"107","author":"Giri","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.3748\/wjg.15.4137","article-title":"Problems associated with glucose toxicity: Role of hyperglycemia-induced oxidative stress","volume":"15","author":"Kawahito","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/dom.12064","article-title":"Inhibition of the sodium glucose co-transporter-2: Its beneficial action and potential combination therapy for type 2 diabetes mellitus","volume":"15","author":"Chen","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Patel, T.A., Zheng, H., and Patel, K.P. (2025). Sodium\u2013Glucose Cotransporter 2 Inhibitors as Potential Antioxidant Therapeutic Agents in Cardiovascular and Renal Diseases. Antioxidants, 14.","DOI":"10.3390\/antiox14030336"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.cgh.2020.05.021","article-title":"SGLT2 Inhibitors in Liver Patients","volume":"18","author":"Hsiang","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Miyamoto, Y., Honda, A., Yokose, S., Nagata, M., and Miyamoto, J. (2023). The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review. J. Clin. Med., 12.","DOI":"10.3390\/jcm12062253"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.2147\/IJGM.S460200","article-title":"Evaluation of MASLD Fibrosis, FIB-4 and APRI Score in MASLD Combined with T2DM and MACCEs Receiving SGLT2 Inhibitors Treatment","volume":"17","author":"Liu","year":"2024","journal-title":"Int. J. Gen. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"108558","DOI":"10.1016\/j.jdiacomp.2023.108558","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials","volume":"37","author":"Jin","year":"2023","journal-title":"J. Diabetes Complicat."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Wei, Q., Xu, X., Guo, L., Li, J., and Li, L. (2021). Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.635556"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41575-021-00520-7","article-title":"Cirrhosis-associated immune dysfunction","volume":"19","author":"Albillos","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Dhoop, S., Shehada, M., Sawaf, B., Patel, M., Roberts, L., Smith, W.-L., and Hart, B. (2024). The Efficacy and Safety of Sodium-Glucose Cotransporter Protein 2 Inhibitors (SGLT2Is) in Liver Cirrhosis: A Systematic Review and Meta-Analysis. medRxiv.","DOI":"10.1101\/2024.12.27.24319638"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Xiao, L., Dai, M., Zhao, F., Shen, Y., Kwan, R.Y.C., Salvador, J.T., Zhang, L., Luo, Y., Liu, Q., and Yang, P. (2023). Assessing the risk factors associated with sarcopenia in patients with liver cirrhosis: A case\u2013control study. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-48955-z"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Zhang, S., Qi, Z., Wang, Y., Song, D., and Zhu, D. (2023). Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1203666"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jama.2023.5997","article-title":"Diagnosis and Management of Cirrhosis and Its Complications: A Review","volume":"329","author":"Tapper","year":"2023","journal-title":"JAMA"},{"key":"ref_62","first-page":"e13175","article-title":"Hyponatremia and Its Correlation With Hepatic Encephalopathy and Severity of Liver Disease","volume":"13","author":"Younas","year":"2021","journal-title":"Cureus"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e0090","DOI":"10.1097\/CLD.0000000000000090","article-title":"Diuretic use in patients with cirrhosis and complications of portal hypertension: Should we rethink the use of furosemide as first line?","volume":"23","author":"Huang","year":"2024","journal-title":"Clin. Liver Dis."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Huynh, D.J., Renelus, B.D., and Jamorabo, D.S. (2023). Reduced mortality and morbidity associated with metformin and SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cirrhosis. BMC Gastroenterol., 23.","DOI":"10.1186\/s12876-023-03085-8"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1111\/dom.14488","article-title":"Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin","volume":"23","author":"Saffo","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_66","first-page":"795","article-title":"SGLT2 Inhibitors: A New Dawn for Recurrent\/Refractory Cirrhotic Ascites","volume":"9","author":"Gao","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/ckj\/sfab266","article-title":"Weaning from concentrated ascites reinfusion therapy for refractory ascites by SGLT2 inhibitor","volume":"15","author":"Miyamoto","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"618","DOI":"10.14309\/ajg.0000000000000995","article-title":"Empagliflozin Eliminates Refractory Ascites and Hepatic Hydrothorax in a Patient With Primary Biliary Cirrhosis","volume":"116","author":"Kalambokis","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/hep.31270","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes","volume":"72","year":"2020","journal-title":"Hepatology"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Seidita, A., Mandreucci, F., Pistone, M., Calderone, S., Giuliano, A., Chiavetta, M., Giannitrapani, L., Citarrella, R., Soresi, M., and Licata, A. (2024). Sodium-glucose cotransporter 2 inhibition in patients with liver cirrhosis and diabetes: A possible role in ascites control?. Ital. J. Med., 18.","DOI":"10.4081\/itjm.2024.1829"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejim.2024.08.012","article-title":"Empagliflozin controls cirrhotic refractory ascites along with improvement of natriuresis and circulatory, cardiac, and renal function: A pilot study","volume":"130","author":"Kalambokis","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.52768\/2766-7820\/2716","article-title":"Sodium glucose co-transporter-2 (SGLT) inhibitors in patients with compensated cirrhosis and diabetes: A prospective study","volume":"4","author":"Praveen","year":"2023","journal-title":"J. Clin. Images Med. Case Rep."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Dhoop, S., Ghazaleh, S., Roberts, L., Shehada, M., Patel, M., Smith, W.-L., Rabeeah, S., Sawaf, B., Vadehra, P., and Hart, B. (2025). Sodium-Glucose Cotransporter-2 Inhibitors in Liver Cirrhosis: A Systematic Review of Their Role in Ascites Management, Slowing Disease Progression, and Safety. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26104781"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"s60","DOI":"10.7861\/clinmedicine.18-2-s60","article-title":"Management of decompensated cirrhosis","volume":"18","author":"Mansour","year":"2018","journal-title":"Clin. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jhep.2021.01.002","article-title":"Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction","volume":"75","author":"Engelmann","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"874","DOI":"10.4065\/71.9.874","article-title":"Ascites and Hepatorenal Syndrome: Pathophysiology and Management","volume":"71","author":"Roberts","year":"1996","journal-title":"Mayo Clin. Proc."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s10620-017-4597-8","article-title":"Electrolyte and Acid\u2013Base Disturbances in End-Stage Liver Disease: A Physiopathological Approach","volume":"62","author":"Torre","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jhep.2014.08.010","article-title":"Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance","volume":"61","author":"Albillos","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Liu, J., Li, L., Li, S., Jia, P., Deng, K., Chen, W., and Sun, X. (2017). Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: A systematic review and meta-analysis. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-02733-w"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","article-title":"SGLT-2 inhibitors and the risk of infections: A systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Puckrin","year":"2018","journal-title":"Acta Diabetol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.japh.2023.10.010","article-title":"Prevalence of sodium-glucose transporter 2 inhibitor-associated diabetic ketoacidosis in real-world data: A systematic review and meta-analysis","volume":"64","author":"Mohammed","year":"2024","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Ata, F., Yousaf, Z., Khan, A.A., Razok, A., Akram, J., Ali, E.A.H., Abdalhadi, A., Ibrahim, D.A., Al Mohanadi, D.H.S.H., and Danjuma, M.I. (2021). SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-89752-w"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.jrn.2022.12.008","article-title":"No Good Deed: Acidosis in Chronic Kidney and Liver Disease","volume":"33","author":"Chandra","year":"2023","journal-title":"J. Ren. Nutr."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/j.jfma.2020.07.013","article-title":"Two alcoholic liver cirrhosis patients developed diabetic ketoacidosis after SGLT2 inhibitors-prescription","volume":"119","author":"Chao","year":"2020","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_85","first-page":"e25870","article-title":"The Impact of Cirrhosis on Outcomes of Patients Admitted With Diabetic Ketoacidosis: A Nationwide Study","volume":"14","author":"Mansour","year":"2022","journal-title":"Cureus"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s40262-013-0126-x","article-title":"Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor","volume":"53","author":"Scheen","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00535-019-01645-y","article-title":"Transition in the etiology of liver cirrhosis in Japan: A nationwide survey","volume":"55","author":"Enomoto","year":"2020","journal-title":"J. Gastroenterol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Adachi, T., Takeuchi, Y., Takaki, A., Oyama, A., Wada, N., Onishi, H., Shiraha, H., and Okada, H. (2021). Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115582"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Jagdish, R.K., Roy, A., Kumar, K., Premkumar, M., Sharma, M., Rao, P.N., Reddy, D.N., and Kulkarni, A.V. (2023). Pathophysiology and management of liver cirrhosis: From portal hypertension to acute-on-chronic liver failure. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1060073"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/hep.27343","article-title":"Molecular pathophysiology of portal hypertension","volume":"61","author":"Fernandez","year":"2015","journal-title":"Hepatology"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Zaccherini, G., Tufoni, M., Iannone, G., and Caraceni, P. (2021). Management of Ascites in Patients with Cirrhosis: An Update. J. Clin. Med., 10.","DOI":"10.3390\/jcm10225226"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Airola, C., Varca, S., Del Gaudio, A., and Pizzolante, F. (2025). The Covert Side of Ascites in Cirrhosis: Cellular and Molecular Aspects. Biomedicines, 13.","DOI":"10.3390\/biomedicines13030680"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.cardfail.2012.10.010","article-title":"Congestive Renal Failure: The Pathophysiology and Treatment of Renal Venous Hypertension","volume":"18","author":"Ross","year":"2012","journal-title":"J. Card. Fail."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Hocher, B., Heiden, S., Von Websky, K., Arafat, A.M., Rahnenf\u00fchrer, J., Alter, M., Kalk, P., Ziegler, D., Fischer, Y., and Pfab, T. (2011). Renal Effects of the Novel Selective Adenosine A1 Receptor Blocker SLV329 in Experimental Liver Cirrhosis in Rats. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0017891"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jhep.2015.07.004","article-title":"Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis","volume":"63","author":"Bernardi","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.1840080532","article-title":"Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis","volume":"8","author":"Schrier","year":"1988","journal-title":"Hepatology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4254\/wjh.v5.i5.251","article-title":"Cirrhotic ascites review: Pathophysiology, diagnosis and management","volume":"5","author":"Moore","year":"2013","journal-title":"World J. Hepatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"74","author":"Biggins","year":"2021","journal-title":"Hepatology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2036.2007.03482.x","article-title":"Review article: Management of ascites and associated complications in patients with cirrhosis","volume":"26","author":"Kuiper","year":"2007","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0168-8278(02)00319-7","article-title":"Nitric oxide mediates the reduced vasoconstrictor response to angiotensin II in patients with preascitic cirrhosis","volume":"38","author":"Helmy","year":"2003","journal-title":"J. Hepatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1098-8823(03)00080-7","article-title":"Eicosanoids in cirrhosis and portal hypertension","volume":"72","author":"Birney","year":"2003","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000462974","article-title":"Molecular Mechanisms Leading to Splanchnic Vasodilation in Liver Cirrhosis","volume":"54","author":"Sacerdoti","year":"2017","journal-title":"J. Vasc. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0016-5085(03)00695-4","article-title":"Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II","volume":"125","author":"Bataller","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11894-020-00783-1","article-title":"Cirrhotic Cardiomyopathy","volume":"22","author":"Yoon","year":"2020","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/gast.2001.25480","article-title":"Angiotensin-Converting Enzyme Inhibition Attenuates the Progression of Rat Hepatic Fibrosis","volume":"121","author":"Jonsson","year":"2001","journal-title":"Gastroenterology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/j.1478-3231.2012.02774.x","article-title":"Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis\u2014A randomized open-label controlled study","volume":"32","author":"Kim","year":"2012","journal-title":"Liver Int."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s12328-019-00956-0","article-title":"Vascular syndromes in liver cirrhosis","volume":"12","author":"Shenoda","year":"2019","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-017-9827-9","article-title":"The portal hypertension syndrome: Etiology, classification, relevance, and animal models","volume":"12","author":"Bosch","year":"2018","journal-title":"Hepatol. Int."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Bitto, N., Ghigliazza, G., Lavorato, S., Caputo, C., and La Mura, V. (2023). Improving Management of Portal Hypertension: The Potential Benefit of Non-Etiological Therapies in Cirrhosis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12030934"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jhep.2018.04.026","article-title":"The relationship of hyperdynamic circulation and cardiodynamic states in cirrhosis","volume":"69","author":"Alvarado","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1002\/hep.20993","article-title":"The Hyperdynamic Circulation of Chronic Liver Diseases: From the Patient to the Molecule","volume":"43","author":"Iwakiri","year":"2006","journal-title":"Hepatology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"100316","DOI":"10.1016\/j.jhepr.2021.100316","article-title":"Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy","volume":"3","author":"Iwakiri","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"688","DOI":"10.4254\/wjh.v7.i4.688","article-title":"Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement","volume":"7","author":"Mura","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII\u2014Renewing consensus in portal hypertension","volume":"76","author":"Bosch","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Stachteas, P., Nasoufidou, A., Patoulias, D., Karakasis, P., Karagiannidis, E., Mourtzos, M.-A., Samaras, A., Apostolidou, X., and Fragakis, N. (2024). The Role of Sodium-Glucose Co-Transporter-2 Inhibitors on Diuretic Resistance in Heart Failure. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063122"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1136\/gut.2006.102764","article-title":"MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation","volume":"56","author":"Londono","year":"2007","journal-title":"Gut"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1038\/ajg.2009.293","article-title":"Hyponatremia Is a Risk Factor of Hepatic Encephalopathy in Patients With Cirrhosis: A Prospective Study With Time-Dependent Analysis","volume":"104","author":"Guevara","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu. Rev. Physiol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1185\/03007995.2014.919907","article-title":"Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)","volume":"30","author":"Weir","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13098-020-00545-z","article-title":"The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease","volume":"12","author":"Ohara","year":"2020","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1463-1326.2012.01659.x","article-title":"Dapagliflozin monotherapy in drug-na\u00efve patients with diabetes: A randomized-controlled trial of low-dose range","volume":"14","author":"Bailey","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/7815690","article-title":"Empagliflozin Increases Short-Term Urinary Volume Output in Artificially Induced Syndrome of Inappropriate Antidiuresis","volume":"2017","author":"Refardt","year":"2017","journal-title":"Int. J. Endocrinol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/cpdd.16","article-title":"Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects","volume":"2","author":"Seman","year":"2013","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, Efficacy and Safety of Sodium\u2013Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e14360","DOI":"10.14814\/phy2.14360","article-title":"Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume","volume":"8","author":"Masuda","year":"2020","journal-title":"Physiol. Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1111\/dme.13107","article-title":"Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes","volume":"33","author":"Wang","year":"2016","journal-title":"Diabet. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1007\/s11606-024-09191-x","article-title":"Empagliflozin in Diuretic-Refractory Ascites (DRAin-Em): Results of a Single-Center Feasibility Study","volume":"40","author":"Hu","year":"2025","journal-title":"J. Gen. Intern. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","author":"Angeli","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jhep.2024.03.031","article-title":"Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting","volume":"81","author":"Nadim","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.clnesp.2023.07.013","article-title":"Sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus and moderate to severe hepatic fibrosis: A retrospective study","volume":"57","author":"Tyagi","year":"2023","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1007\/s00535-024-02158-z","article-title":"Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: A nationwide database study in Japan","volume":"59","author":"Kawaguchi","year":"2024","journal-title":"J. Gastroenterol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Asada, S., Kaji, K., Nishimura, N., Koizumi, A., Matsuda, T., Tanaka, M., Yorioka, N., Sato, S., Kitagawa, K., and Namisaki, T. (2024). Tofogliflozin Delays Portal Hypertension and Hepatic Fibrosis by Inhibiting Sinusoidal Capillarization in Cirrhotic Rats. Cells, 13.","DOI":"10.3390\/cells13060538"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/liv.15897","article-title":"The associations between fibrosis changes and liver-related events in patients with metabolic dysfunction-associated steatotic liver disease","volume":"44","author":"Lee","year":"2024","journal-title":"Liver Int."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1681\/ASN.0000000000000436","article-title":"Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD","volume":"35","author":"Smeijer","year":"2024","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/HEP.0000000000000837","article-title":"Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: A Mendelian randomization and population-based cohort study","volume":"80","author":"Chung","year":"2024","journal-title":"Hepatology"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e43765","DOI":"10.34172\/ipp.2025.43765","article-title":"Systematic review and meta-analysis of the association between the use of SGLT2 inhibitors and hepatocellular carcinoma","volume":"11","author":"Shabani","year":"2025","journal-title":"Immunopathol. Persa"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/gutjnl-2020-321790","article-title":"Guidelines on the management of ascites in cirrhosis","volume":"70","author":"Aithal","year":"2021","journal-title":"Gut"},{"key":"ref_139","first-page":"1","article-title":"Update on cirrhotic cardiomyopathy: From etiopathogenesis to treatment","volume":"37","author":"Yumusak","year":"2024","journal-title":"Ann. Gastroenterol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"102388","DOI":"10.1016\/j.cpcardiol.2024.102388","article-title":"SGLT2 inhibitors in heart failure with preserved ejection fraction","volume":"49","author":"Faluk","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"774","DOI":"10.2215\/CJN.12451018","article-title":"Hepatorenal Syndrome","volume":"14","author":"Francoz","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1124\/jpet.122.001289","article-title":"Sodium-Glucose Cotransporter-2 Inhibition Exacerbates Hepatic Encephalopathy in Biliary Cirrhotic Rats","volume":"383","author":"Hsu","year":"2022","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10620-014-3432-8","article-title":"Recent Advances in Cirrhotic Cardiomyopathy","volume":"60","author":"Karagiannakis","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nrgastro.2013.210","article-title":"Cirrhotic cardiomyopathy: Pathogenesis and clinical relevance","volume":"11","author":"Wiese","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1172\/JCI102813","article-title":"THE CARDIAC OUTPUT AT REST IN LAENNEC\u2019S CIRRHOSIS 1","volume":"32","author":"Kowalski","year":"1953","journal-title":"J. Clin. Investig."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1478-3231.2011.02468.x","article-title":"Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging: Myocardial function in cirrhosis","volume":"31","author":"Kazankov","year":"2011","journal-title":"Liver Int."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"107913","DOI":"10.1016\/j.jdiacomp.2021.107913","article-title":"Early left ventricular systolic dysfunction in asymptomatic patients with type 1 diabetes: A single-center, pilot study","volume":"35","author":"Kapelios","year":"2021","journal-title":"J. Diabetes Complicat."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1253\/circj.CJ-15-0012","article-title":"Subendocardial Systolic Dysfunction in Asymptomatic Normotensive Diabetic Patients","volume":"79","author":"Enomoto","year":"2015","journal-title":"Circ. J."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/ejechocard\/jep097","article-title":"Subclinical left ventricular dysfunction in asymptomatic diabetic patients assessed by two-dimensional speckle tracking echocardiography: Correlation with diabetic duration","volume":"10","author":"Nakai","year":"2009","journal-title":"Eur. J. Echocardiogr."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Gamaza-Chuli\u00e1n, S., D\u00edaz-Retamino, E., Gonz\u00e1lez-Test\u00f3n, F., Gaitero, J.C., Castillo, M.J., Alfaro, R., Rodr\u00edguez, E., Gonz\u00e1lez-Caballero, E., and Mart\u00edn-Santana, A. (2021). Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: A prospective observational study. BMC Cardiovasc. Disord., 21.","DOI":"10.1186\/s12872-021-02250-9"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Kloza, M., Krzy\u017cewska, A., Koz\u0142owska, H., Budziak, S., and Baranowska-Kuczko, M. (2025). Empagliflozin Plays Vasoprotective Role in Spontaneously Hypertensive Rats via Activation of the SIRT1\/AMPK Pathway. Cells, 14.","DOI":"10.3390\/cells14070507"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Satyam, S.M., Bairy, L.K., Rehman, A., Attia, M., Ahmed, L., Emad, K., Jaafer, Y., and Bahaaeldin, A. (2024). Unlocking Synergistic Hepatoprotection: Dapagliflozin and Silymarin Combination Therapy Modulates Nuclear Erythroid 2-Related Factor 2\/Heme Oxygenase-1 Pathway in Carbon Tetrachloride-Induced Hepatotoxicity in Wistar Rats. Biology, 13.","DOI":"10.3390\/biology13070473"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Fu, C., Deng, L., Zhu, X., Wang, B., Hu, B., Xue, H., Zeng, Q., and Zhang, Y. (2025). Empagliflozin Attenuates Liver Inflammation and Fibrosis in NAFLD: Evidence from Mendelian Randomization and Mouse Experiments. Curr. Issues Mol. Biol., 47.","DOI":"10.3390\/cimb47100846"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Heo, Y.J., Park, J., Lee, N., Choi, S.-E., Jeon, J.Y., Han, S.J., Kim, D.J., Lee, K.W., and Kim, H.J. (2025). Empagliflozin Alleviates Hepatic Steatosis and Oxidative Stress via the NRF1 Pathway in High-Fat Diet-Induced Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26094054"},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Suki, M., Imam, A., Amer, J., Milgrom, Y., Massarwa, M., Hazou, W., Tiram, Y., Perzon, O., Sharif, Y., and Sackran, J. (2025). SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic. Pharmaceuticals, 18.","DOI":"10.3390\/ph18081118"},{"key":"ref_158","first-page":"e250015","article-title":"SGLT2 inhibitor administration to two patients with diabetes mellitus with ascites due to cirrhosis","volume":"2025","author":"Nagayama","year":"2025","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Asakura-Kinoshita, M., Masuda, T., Oka, K., Ohara, K., Miura, M., Morinari, M., Misawa, K., Miyazawa, Y., Akimoto, T., and Shimada, K. (2024). Sodium\u2013Glucose Cotransporter 2 Inhibitor Combined with Conventional Diuretics Ameliorate Body Fluid Retention without Excessive Plasma Volume Reduction. Diagnostics, 14.","DOI":"10.3390\/diagnostics14111194"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Stratina, E., Stanciu, C., Nastasa, R., Zenovia, S., Stafie, R., Rotaru, A., Cuciureanu, T., Muzica, C., Sfarti, C., and Girleanu, I. (2024). New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease. Diagnostics, 14.","DOI":"10.3390\/diagnostics14141475"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez Campos, E., Grover P\u00e1ez, F., Ramos Becerra, C.G., Balleza Alejandri, L.R., Su\u00e1rez Rico, D.O., Cardona Mu\u00f1oz, E.G., Pascoe Gonz\u00e1lez, S., Ramos Zavala, M.G., Beltr\u00e1n Ram\u00edrez, A., and Garc\u00eda Galindo, J.J. (2025). Empagliflozin Leads to Faster Improvement in Arterial Stiffness Compared to Dapagliflozin: A Double-Blind Clinical. Life, 15.","DOI":"10.3390\/life15050802"},{"key":"ref_162","first-page":"701","article-title":"Complete Resolution of Refractory Ascites and Pleural Effusion with Sustained Improvement in Urinary Sodium Excretion in a Cirrhotic Patient Treated with Empagliflozin","volume":"13","author":"Qin","year":"2025","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/ajh\/hpae092","article-title":"State-of-the-Art-Review: Mechanisms of Action of SGLT2 Inhibitors and Clinical Implications","volume":"37","author":"Vallon","year":"2024","journal-title":"Am. J. Hypertens."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s40620-025-02305-6","article-title":"Contributing factors and clinical usefulness of spot urine glucose-to-creatinine ratio by sodium glucose cotransporter 2 inhibitors: A cross-sectional study","volume":"38","author":"Nagai","year":"2025","journal-title":"J. Nephrol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/db23-0448","article-title":"Role of Glycosuria in SGLT2 Inhibitor\u2013Induced Cardiorenal Protection: A Mechanistic Analysis of the CREDENCE Trial","volume":"73","author":"Ferrannini","year":"2024","journal-title":"Diabetes"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2025.03.503","article-title":"Effect of Empagliflozin on the Mechanisms Driving Erythropoiesis and Iron Mobilization in Patients With Heart Failure","volume":"85","author":"Ferreira","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_171","first-page":"165","article-title":"Effect of SGLT2 inhibitors on anemia and their possible clinical implications","volume":"44","author":"Cases","year":"2024","journal-title":"Nefrol. Engl. Ed."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S2213-8587(20)30185-6","article-title":"Reductions in albuminuria with SGLT2 inhibitors: A marker for improved renal outcomes in patients without diabetes?","volume":"8","author":"Sternlicht","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jacc.2023.10.030","article-title":"Hyperuricemia and Gout Reduction by SGLT2 Inhibitors in Diabetes and Heart Failure","volume":"83","author":"Packer","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"e003836","DOI":"10.1136\/bmjdrc-2023-003836","article-title":"Effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on serum uric acid levels in patients with chronic kidney disease: A systematic review and network meta-analysis","volume":"12","author":"Zhang","year":"2024","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Darwish, D., Kumar, P., Urs, K., and Dave, S. (2025). Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure. Cells, 14.","DOI":"10.3390\/cells14120919"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"132239","DOI":"10.1016\/j.ijcard.2024.132239","article-title":"Effect of sodium-glucose co-transporter 2 inhibitors (SGLT2i) on N-terminal pro-B-type natriuretic peptide (NT-proBNP) level and structural changes following myocardial infarction: A systematic review and meta-analysis","volume":"410","author":"Banjar","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s40262-024-01443-7","article-title":"SGLT2 Inhibitors in Patients with Heart Failure: A Model-Based Meta-Analysis","volume":"63","author":"Wang","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jhep.2016.07.003","article-title":"Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis","volume":"65","author":"Kerbert","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Hartl, L., Hintersteininger, M., Simbrunner, B., Jachs, M., Hofer, B.S., Bauer, D.J.M., Dominik, N., Schwarz, M., Balcar, L., and Kramer, G. (2025). The Vasopressin Biomarker Copeptin is Linked to Systemic Inflammation and Refines Prognostication in Decompensated Cirrhosis. Clin. Gastroenterol. Hepatol., S1542356525004616.","DOI":"10.1016\/j.cgh.2025.04.030"},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Masuda, T., Asakura-Kinoshita, M., Oka, K., Ohara, K., Sakai, M., Miura, M., Misawa, K., Hirai, K., Morinari, M., and Akimoto, T. (2025). SGLT2 inhibitor requires co-administration with diuretics to effectively reduce interstitial fluid retention: The DAPA-BODY trial. Hypertens. Res.","DOI":"10.1038\/s41440-025-02388-5"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s12020-025-04393-7","article-title":"Risk of genitourinary tract infections with SGLT-2 inhibitors in type 2 diabetes mellitus: A meta-analysis of randomised controlled trials and disproportionality analysis using FAERS","volume":"90","author":"Yoosuf","year":"2025","journal-title":"Endocrine"},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Wu, M.-Z., Guo, R., Chandramouli, C., Liu, L., Tung, A.M.-O., Tsang, C.T.-W., Tse, Y.-K., Chan, Y.-H., Lee, C.-H., and Huang, J.-Y. (2025). Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients. Eur. Heart J., ehaf788.","DOI":"10.1093\/eurheartj\/ehaf788"},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Pan, R., Zhang, Y., Wang, R., Xu, Y., Ji, H., and Zhao, Y. (2022). Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0279889"},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Volpe, S., Vozza, A., Lisco, G., Fanelli, M., Racaniello, D., Bergamasco, A., Triggiani, D., Pierangeli, G., De Pergola, G., and Tortorella, C. (2024). Sodium-Glucose Cotransporter 2 Inhibitors Improve Body Composition by Increasing the Skeletal Muscle Mass\/Fat Mass Ratio in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study. Nutrients, 16.","DOI":"10.3390\/nu16223841"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"e003666","DOI":"10.1136\/bmjdrc-2023-003666","article-title":"Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors","volume":"11","author":"Chow","year":"2023","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_186","first-page":"17","article-title":"Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature","volume":"7","author":"Mistry","year":"2021","journal-title":"AACE Clin. Case Rep."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/12\/1788\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T09:23:39Z","timestamp":1763717019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/12\/1788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":186,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["life15121788"],"URL":"https:\/\/doi.org\/10.3390\/life15121788","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]}}}